Cargando…
1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212638/ http://dx.doi.org/10.1016/S0016-5085(22)60657-7 |
| _version_ | 1784730646512402432 |
|---|---|
| author | Wellens, Judith Edmans, Matthew Obolski, Uri Marlow, Luke Brann, Stephanie Dunachie, Susanna Eyre, David W. Helmus, Drew Barnes, Eleanor Colombel, Jean Frederic Wong, Serre-Yu Klenerman, Paul Lindsay, James O. Thompson, Craig Satsangi, Jack J. |
| author_facet | Wellens, Judith Edmans, Matthew Obolski, Uri Marlow, Luke Brann, Stephanie Dunachie, Susanna Eyre, David W. Helmus, Drew Barnes, Eleanor Colombel, Jean Frederic Wong, Serre-Yu Klenerman, Paul Lindsay, James O. Thompson, Craig Satsangi, Jack J. |
| author_sort | Wellens, Judith |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212638 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92126382022-06-22 1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE Wellens, Judith Edmans, Matthew Obolski, Uri Marlow, Luke Brann, Stephanie Dunachie, Susanna Eyre, David W. Helmus, Drew Barnes, Eleanor Colombel, Jean Frederic Wong, Serre-Yu Klenerman, Paul Lindsay, James O. Thompson, Craig Satsangi, Jack J. Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212638/ http://dx.doi.org/10.1016/S0016-5085(22)60657-7 Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AGA Abstracts Wellens, Judith Edmans, Matthew Obolski, Uri Marlow, Luke Brann, Stephanie Dunachie, Susanna Eyre, David W. Helmus, Drew Barnes, Eleanor Colombel, Jean Frederic Wong, Serre-Yu Klenerman, Paul Lindsay, James O. Thompson, Craig Satsangi, Jack J. 1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE |
| title | 1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE |
| title_full | 1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE |
| title_fullStr | 1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE |
| title_full_unstemmed | 1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE |
| title_short | 1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE |
| title_sort | 1163: both vedolizumab and anti-tnf therapy are associated with attenuation of serological and neutralizing responses to sars-cov-2 infection in inflammatory bowel disease |
| topic | AGA Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212638/ http://dx.doi.org/10.1016/S0016-5085(22)60657-7 |
| work_keys_str_mv | AT wellensjudith 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT edmansmatthew 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT obolskiuri 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT marlowluke 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT brannstephanie 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT dunachiesusanna 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT eyredavidw 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT helmusdrew 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT barneseleanor 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT colombeljeanfrederic 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT wongserreyu 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT klenermanpaul 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT lindsayjameso 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT thompsoncraig 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease AT satsangijackj 1163bothvedolizumabandantitnftherapyareassociatedwithattenuationofserologicalandneutralizingresponsestosarscov2infectionininflammatoryboweldisease |